Terminated PHASE2 INTERVENTIONAL 1-arm NCT00505921

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Autologous and Allogeneic Transplantation for T-Cell Lymphoma: Impact of Campath -1H and Soluble CD52

Sponsor: Bayer

Conditions Lymphoma

Interventions BCNU Campath Campath-1H Cyclophosphamide Cytarabine Etoposide Fludarabine G-CSF GM-CSF Low dose total body irradiation Melphalan Preparative Regimen for Allogenic Stem Cell Transplantation Stem Cell Transplant

Updated 6 times since 2017 Last updated: Nov 8, 2011 Started: Mar 31, 2003 Primary completion: Nov 30, 2009 Completion: Nov 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow Accrual.

Other terminated trials from Bayer

See all terminations from Bayer

Other Lymphoma trials with similar outcome

Browse all Lymphoma trials

A PHASE2 clinical study on Lymphoma, this trial is terminated or withdrawn. The trial is conducted by Bayer and has accumulated 6 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States